AVTX

Avalo is a clinical-stage biotech with effectively no commercial business — FY2025 revenue was $59K (down 86.6% YoY, and just residual Millipred reserve adjustments after the license expired in September 2023). Operating loss was $72.9M and net loss was $78.3M on operating cash burn of $51.5M. The entire equity story rests on a single asset, abdakibart (AVTX-009), an anti-IL-1 mAb in the Phase 2 LOTUS trial in hidradenitis suppurativa, with topline data 'expected in the second quarter of 2026' per the MD&A. At $18.41 and a 22.8M share count (up 113.5% YoY, signaling a recent capital raise), market cap is ~$420M against $59K of revenue — a P/S of 7,112x that is meaningless except as a marker that the price is 100% a bet on the LOTUS readout.

The filing's own language is unusually candid about the binary setup. Management says cash of $98.3M (10-K date, vs. $15.9M cash-only on the balance sheet plus short-term investments) funds operations 'into 2028,' but explicitly warns it 'will likely need to raise additional funds prior to any phase 3 development' and could need them sooner if 'there are significant unexpected delays and/or cost overruns in our current Phase 2 LOTUS trial.' R&D rose from $24.4M to $50.1M YoY — clinical expenses alone went from $10.0M to $24.9M — so burn is accelerating into the readout. The Risk Factors flatly contemplate having to 'significantly delay, scale back or discontinue' development or 'cease operations altogether' if capital markets close. Accumulated deficit is -$449M and total liabilities jumped 88.8% YoY.